RNA aggregates harness the danger response for potent cancer immunotherapy.
Cell
; 187(10): 2521-2535.e21, 2024 May 09.
Article
in En
| MEDLINE
| ID: mdl-38697107
ABSTRACT
Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create "onion-like" multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting massive cytokine/chemokine response and dendritic cell/lymphocyte trafficking that provokes cancer immunogenicity and mediates rejection of both early- and late-stage murine tumor models. In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became "hot" within days of a single infusion. In a first-in-human trial, RNA-LPAs elicited rapid cytokine/chemokine release, immune activation/trafficking, tissue-confirmed pseudoprogression, and glioma-specific immune responses in glioblastoma patients. These data support RNA-LPAs as a new technology that simultaneously reprograms the TME while eliciting rapid and enduring cancer immunotherapy.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
RNA
/
Tumor Microenvironment
/
Immunotherapy
/
Lipids
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Cell
Year:
2024
Type:
Article
Affiliation country:
United States